Illustrative

FDA’s One Trial Policy Not a Revolution but a Potentially Risky Evolution

BioSpace·Feb 26

This story is reported by BioSpace. Read what other outlets are saying below, then open the original report for full details.

Full coverage

1

Eli Lilly gave extraordinary obesity drug access to a 79-year-old patient. Who was it?

STAT·Jun 23

2

How The Quiet Data Standards Revolution Is Impacting Drug Approval

Clinical Leader·Jun 11

3

First RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to Know

Pancreatic Cancer Action Network·Jun 1

4

New pancreatic cancer drug withheld as family fights for access

Treasure Coast News·Jun 23

5

The FDA Said No. Europe Said Yes. Someone Is Wrong About Camizestrant.

The Clinical Trial Vanguard·May 26

6

FDA Changes Drug Trial Guidance: Experts Take Sides

Medscape·Feb 18

7

New Hope for Pancreatic Cancer With Targeted KRAS Drug

Memorial Sloan Kettering Cancer Center·May 7

8

Expanded access to daraxonrasib signals ‘dawn of a new era’ in pancreatic cancer treatment

Healio·May 5